- Verismo Therapeutics has successfully manufactured its first clinical cell product for the STAR-101 trial using lentiviral vector supplied by Miltenyi Bioindustry.
- The collaboration supports development of SynKIR™-110, a CAR T therapy targeting mesothelin in solid tumours.
Verismo Therapeutics, a clinical-stage CAR T company, has announced the successful manufacture of its first clinical cell product for STAR-101, a Phase 1 trial of its lead candidate SynKIR™-110. The product was manufactured using lentiviral vector supplied by Miltenyi Bioindustry, the contract development and manufacturing organisation (CDMO) division of Miltenyi Biotec.
The achievement represents a milestone in the STAR-101 trial and is intended to support later-stage development of SynKIR™-110 for the treatment of solid tumours. By securing a reliable lentiviral vector supply, Verismo aims to prepare for Phase 2 trials and potential future commercial applications.
Miltenyi Bioindustry provides services in design, construction, and GMP manufacturing of viral vectors. The collaboration reflects its role in supporting the translation of cell and gene therapies into clinical settings.
“Our collaboration with Miltenyi Bioindustry plays a key role as we scale our programs. This partnership reflects Verismo’s commitment to ensuring manufacturing continuity and Phase 2 clinical readiness.”
Dr Bryan Kim, CEO of Verismo Therapeutics
Stefan Miltenyi, founder and CEO of Miltenyi Biotec, added that the company is proud to support Verismo’s work in next-generation CAR T therapies, highlighting the alignment of both companies in advancing innovative treatments.
